Dynavax Technologies (NASDAQ:DVAX) Announces Earnings Results

Dynavax Technologies (NASDAQ:DVAX) announced its earnings results on Wednesday. The biopharmaceutical company reported $0.21 EPS for the quarter, topping the consensus estimate of $0.14 by $0.07, Zacks reports. The company had revenue of $94.88 million for the quarter, compared to analysts’ expectations of $94.00 million. Dynavax Technologies had a negative net margin of 16.67% and a positive return on equity of 5.10%.

Dynavax Technologies Price Performance

Dynavax Technologies stock traded down $0.21 during mid-day trading on Friday, reaching $10.79. The company had a trading volume of 1,345,936 shares, compared to its average volume of 1,984,416. The business has a fifty day simple moving average of $10.00 and a 200 day simple moving average of $10.29. The company has a market cap of $1.26 billion, a P/E ratio of -23.45 and a beta of 1.09. Dynavax Technologies has a fifty-two week low of $9.20 and a fifty-two week high of $14.63. The company has a current ratio of 6.65, a quick ratio of 6.01 and a debt-to-equity ratio of 0.45.

Insider Activity at Dynavax Technologies

In other news, Director Scott Dunseth Myers acquired 3,800 shares of the business’s stock in a transaction that occurred on Friday, August 22nd. The shares were bought at an average price of $10.82 per share, with a total value of $41,116.00. Following the acquisition, the director directly owned 35,004 shares in the company, valued at $378,743.28. The trade was a 12.18% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 2.98% of the company’s stock.

Hedge Funds Weigh In On Dynavax Technologies

Large investors have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Dynavax Technologies by 1.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 86,421 shares of the biopharmaceutical company’s stock worth $1,126,000 after purchasing an additional 1,625 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Dynavax Technologies in the 1st quarter valued at approximately $180,000. Caxton Associates LLP bought a new position in shares of Dynavax Technologies during the first quarter valued at $225,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Dynavax Technologies by 7.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 450,089 shares of the biopharmaceutical company’s stock worth $5,838,000 after purchasing an additional 29,764 shares during the last quarter. Finally, Baird Financial Group Inc. acquired a new stake in Dynavax Technologies in the second quarter valued at $136,000. 96.96% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on DVAX. Wall Street Zen raised Dynavax Technologies from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Weiss Ratings reiterated a “sell (d)” rating on shares of Dynavax Technologies in a research note on Wednesday, October 8th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $32.00 price target on shares of Dynavax Technologies in a report on Friday, August 22nd. Three analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $24.33.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.